First Patient dosed in Ph 1 Trial of GIGA-564 in Advanced Solid Tumors
“The initiation of this Phase 1 trial with GIGA-564 marks a significant milestone as it is GigaGen’s first oncology asset to enter the clinic,” said Carter Keller, senior vice president of Grifols and head of GigaGen. “We look forward to potentially translating the superior anti-tumor performance and reduced immune-related toxicity observed with GIGA-564 in pre-clinical studies into the clinical setting. There is a pressing need for innovative therapies for solid tumors and we believe GIGA-564 has the potential to improve outcomes for patients.”
Share:
More News
“The initial efficacy data from the Part C studies are consistent with the encouraging efficacy signals we previously reported for Parts A and B of THIO-101, including an 88% disease control rate in third-line NSCLC patients. This measure of efficacy is close to triple the reported outcome for standard-of-care chemotherapy
“Patients with non-muscle invasive bladder cancer continue to face a significant risk of disease recurrence despite available treatment options,” said Mark Schoenberg, M.D., Chief Medical Officer of UroGen. “UGN-501 is an investigational next-generation oncolytic virus designed to selectively destroy tumor cells while generating an anti-tumor immune response. FDA clearance of
“Whitehawk has established strong expertise in ADC technology and oncology drug development,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “This collaboration further expands the application of Biocytogen’s fully human bispecific antibodies in ADC development. We look forward to supporting the efficient advancement of multiple programs by contributing high-quality
Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “The AZUR-1 results support the potential for dostarlimab to transform treatment for dMMR/MSI-H locally advanced rectal cancer. For many patients today, rectal cancer treatment comes with the tolerability burden and lasting impacts from chemotherapy, radiation and surgery. These data